Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Gene Logic, Inc. (NasdaqNM:GLGC)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Options | Financials | Reports
Location
708 Quince Orchard Road
Gaithersburg, MD 20878
Phone: (301) 987-1700
Fax: (301) 987-1701
Email: investors@genelogic.com
Employees (last reported count): 226
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Free Annual Report
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Websites
 ·Home Page
 ·Investor Relations
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 44%
·Over the last 6 months:
 · 5 insider sells; 232.0K shares
  (1.9% of insider shares)
·Institutional: 77% (138% of float)
(182 institutions)
·Net Inst. Buying: 1.11M shares (+5.11%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Gene Logic, Inc. is a supplier of integrated genomic information and bioinformatics related to gene activity in human disease and toxicity to enable global pharmaceutical, biotechnology, life sciences and diagnostic companies to reduce the time, risk and cost involved in developing drugs against human disease. Through the systematic and industrialized application of genomics, the Company has built and is commercializing what it believes to be the world's most comprehensive survey of gene expression from human and animal tissues. The Company markets a growing portfolio of gene expression-based products. These products include the Company's flagship product, the GeneExpress Suite of databases, and custom, proprietary gene expression databases focused on single disease indications.
More from Market Guide: Expanded Business Description

Financial Summary
GLGC provides genomic information, enabling the discovery and development of pharmaceutical, biotechnology, and life science products through the systematic and industrialized application of genomics. For the six months ended 6/30/01, revenues rose 47% to $17.8 million. Net loss before acct. change totaled $20 million, up from $9.5 million. Results reflect increased subscriptions for the GeneExpressTM, offset by increased tissue acquisition and processing costs.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Compensation
PayExer

Mark Gessler, 39
Chairman, Pres, CEO
$888K$5.6M
Philip Rohrer, Jr., 44
CFO
--  --  
Victor Markowitz, 48
Sr. VP, CIO
400K938K
Eric Eastman,P.h.D., 48
Sr. VP, CTO
286K183K
David Murray, 54
Sr. VP, Marketing and Sales
603K--  
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year.
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:GLGCAs of 31-Aug-2001
Price and Volume
52-Week Low
on 22-Mar-2001
$12.75 
Recent Price$17.45 
52-Week High
on 1-Sep-2000
$27.75 
Beta1.51 
Daily Volume (3-month avg)224.7K
Daily Volume (10-day avg)138.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y]
52-Week Change-34.6%
52-Week Change
relative to S&P500
-12.3%
Share-Related Items
Market Capitalization$465.4M
Shares Outstanding26.7M
Float14.9M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$8.93 
Earnings (ttm)-$1.27 
Earnings (mrq)-$0.35 
Sales (ttm)$1.25 
Cash (mrq)$7.61 
Valuation Ratios
Price/Book (mrq)1.95 
Price/EarningsN/A 
Price/Sales (ttm)14.00 
Income Statements
Sales (ttm)$32.6M
EBITDA (ttm)-$43.2M
Income available to common (ttm)-$33.2M
Profitability
Profit Margin (ttm)-97.4%
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-11.45%
Return on Equity (ttm)-13.16%
Financial Strength
Current Ratio (mrq)10.00 
Debt/Equity (mrq)0.01 
Total Cash (mrq)$202.5M
Short Interest
As of 8-Aug-2001
Shares Short1.09M
Percent of Float7.3%
Shares Short
(Prior Month)
1.20M
Short Ratio6.92 
Daily Volume157.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.